PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

• DOI: 10.3389/fimmu.2023.1326078
• Publication Date: 2024-01-10T04:32:06Z
• Authors: Lorenz Kocheise; Ignazio Piseddu; Joscha Vonderlin; Eric T. Tjwa; Gustav Buescher; Lucy Meunier; Pia Goeggelmann; Francesca Fianchi; Jérôme Dumortier; Mar Riveiro Barciela; Tom J. G. Gevers; Benedetta Terziro...; Maria-Carlota Lon...; Sona Frankova; Thomas Roesner; Vincent Joerg; Constantin Schmidt; Fabian Glaser; Jan P. Sutter; Thorben W. Fründt; Ansgar W. Lohse; Samuel Huber; Johann von Felden; Marcial Sebode; Kornelius Schulze
• Keywords: Autoimmune Hepatitis; Durvalumab; Atezolizumab; Primary Sclerosing Cholangitis

Introduction Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern clinical practice. The safety profile ICI for patients diagnosed with autoimmune and cholestatic liver disease (AILD) remains unclear. Due to this uncertainty, these were excluded from trials withheld patient group. In retrospective multicenter study, we assessed AILD. Methods We contacted tertiary referral hospitals identification AILD under Europe via European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Fourteen centers contributed data being treated ICI, another three did not treat due fear irAEs. Results 22 could be identified. Among patients, 12 had primary biliary cholangitis (PBC), five sclerosing (PSC), four hepatitis (AIH), one an AIH-PSC variant syndrome. Eleven hepatobiliary cancers other 11 presented non-hepatic tumors. applied ICIs atezolizumab (n=7), durvalumab (n=5), pembrolizumab (n=4), nivolumab spartalizumab (n=1), case combined immunotherapy plus ipilimumab. eight who grade 1 or 2 irAEs, demonstrated Cases grades ≥ 3 irAEs reported. No significant changes tests observed during first year after start ICI. Discussion This study demonstrates that PD-1/PD-L1 appear safe Further studies more potent dual immune therapy needed. conclude should categorically